{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:57:05Z","timestamp":1791381425408,"version":"4.3.3"},"reference-count":285,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>\u03b1-Synuclein (asyn) is a key pathogenetic factor in a group of neurodegenerative diseases generically known as synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). Although the initial triggers of pathology and progression are unclear, multiple lines of evidence support therapeutic targeting of asyn in order to limit its prion-like misfolding. Here, we review recent pre-clinical and clinical work that offers promising treatment strategies to sequester, degrade, or silence asyn expression as a means to reduce the levels of seed or substrate. These diverse approaches include removal of aggregated asyn with passive or active immunization or by expression of vectorized antibodies, modulating kinetics of misfolding with small molecule anti-aggregants, lowering asyn gene expression by antisense oligonucleotides or inhibitory RNA, and pharmacological activation of asyn degradation pathways. We also discuss recent technological advances in combining low intensity focused ultrasound with intravenous microbubbles to transiently increase blood-brain barrier permeability for improved brain delivery and target engagement of these large molecule anti-asyn biologics.<\/jats:p>","DOI":"10.3389\/fneur.2022.852003","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T02:36:33Z","timestamp":1652063793000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":101,"title":["Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies"],"prefix":"10.3389","volume":"13","author":[{"given":"Sindhu","family":"Menon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Hamzeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi P.","family":"Visanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Pablo","family":"Sardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","article-title":"100 years of Lewy pathology","volume":"9","author":"Goedert","year":"2013","journal-title":"Nat Rev Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"B3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s12035-012-8334-1","article-title":"Targeting the chameleon: a focused look at alpha-synuclein and its roles in neurodegeneration","volume":"47","author":"Silva","year":"2013","journal-title":"Mol Neurobiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"a024091","DOI":"10.1101\/cshperspect.a024091","article-title":"Cell biology and pathophysiology of alpha-synuclein","volume":"8","author":"Burre","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1074\/jbc.REV118.006493","article-title":"Intrinsically disordered proteins in synaptic vesicle trafficking and release","volume":"294","author":"Snead","year":"2019","journal-title":"J Biol Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/jnen\/nlaa109","article-title":"Risk of transmissibility from neurodegenerative disease-associated proteins: experimental knowns and unknowns","volume":"79","author":"Asher","year":"2020","journal-title":"J Neuropathol Exp Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease3","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nat Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"III\/1","DOI":"10.1007\/s00415-002-1301-4","article-title":"Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages)","volume":"249","author":"Braak","year":"2002","journal-title":"J.Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00401-010-0664-3","article-title":"Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders","volume":"119","author":"Beach","year":"2010","journal-title":"Acta Neuropathol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3389\/fnins.2018.00344","article-title":"Import and export of misfolded alpha-synuclein","volume":"12","author":"Rodriguez","year":"2018","journal-title":"Front Neurosci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"13010","DOI":"10.1073\/pnas.0903691106","article-title":"Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein","volume":"106","author":"Desplats","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI43366","article-title":"alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells1","volume":"121","author":"Hansen","year":"2011","journal-title":"J Clin Invest."},{"key":"B14","doi-asserted-by":"publisher","first-page":"20051","DOI":"10.1073\/pnas.0908005106","article-title":"Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells2","volume":"106","author":"Luk","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death1","volume":"72","author":"Volpicelli-Daley","year":"2011","journal-title":"Neuron."},{"key":"B16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.nbd.2014.07.003","article-title":"A cell culture model for monitoring alpha-synuclein cell-to-cell transfer","volume":"77","author":"Reyes","year":"2014","journal-title":"Neurobiol Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"E4949","DOI":"10.1073\/pnas.1513426112","article-title":"Propagation of prions causing synucleinopathies in cultured cells","volume":"112","author":"Woerman","year":"2015","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B18","doi-asserted-by":"publisher","first-page":"13482","DOI":"10.1074\/jbc.M117.780296","article-title":"Selective imaging of internalized proteopathic alpha-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies","volume":"292","author":"Karpowicz RJ","year":"2017","journal-title":"J Biol Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00401-013-1160-3","article-title":"Transfer of human alpha-synuclein from the olfactory bulb to interconnected brain regions in mice","volume":"126","author":"Rey","year":"2013","journal-title":"Acta Neuropathol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1084\/jem.20160368","article-title":"Widespread transneuronal propagation of alpha-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease","volume":"213","author":"Rey","year":"2016","journal-title":"J Exp Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1016\/j.neurobiolaging.2011.06.022","article-title":"Prion-like acceleration of a synucleinopathy in a transgenic mouse model","volume":"33","author":"Mougenot","year":"2012","journal-title":"Neurobiol Aging."},{"key":"B22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1084\/jem.20112457","article-title":"Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice","volume":"209","author":"Luk","year":"2012","journal-title":"J Exp Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1073\/pnas.1318268110","article-title":"Transmission of multiple system atrophy prions to transgenic mice","volume":"110","author":"Watts","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B24","doi-asserted-by":"publisher","first-page":"12368","DOI":"10.1523\/JNEUROSCI.2102-14.2014","article-title":"Brain injection of alpha-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker","volume":"34","author":"Sacino","year":"2014","journal-title":"J Neurosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrn.2016.178","article-title":"Selective neuronal vulnerability in Parkinson disease","volume":"18","author":"Surmeier","year":"2017","journal-title":"Nat Rev Neurosci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"9808","DOI":"10.1523\/JNEUROSCI.1788-16.2017","article-title":"Prying into the prion hypothesis for Parkinson's disease","volume":"37","author":"Brundin","year":"2017","journal-title":"J Neurosci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00401-019-02010-2","article-title":"Selective vulnerability in alpha-synucleinopathies","volume":"138","author":"Alegre-Abarrategui","year":"2019","journal-title":"Acta Neuropathol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41593-019-0541-x","article-title":"alpha-Synuclein strains target distinct brain regions and cell types","volume":"23","author":"Lau","year":"2020","journal-title":"Nat Neurosci."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab440","article-title":"Differentially targeted seeding reveals unique pathological alpha-synuclein propagation patterns","author":"Rahayel","year":"2021","journal-title":"Brain"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1038\/ncomms3575","article-title":"Structural and functional characterization of two alpha-synuclein strains","volume":"4","author":"Bousset","year":"2013","journal-title":"Nat Commun."},{"key":"B31","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature14547","article-title":"alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration","volume":"522","author":"Peelaerts","year":"2015","journal-title":"Nature."},{"key":"B32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00401-019-02058-0","article-title":"Calling alpha-synuclein a prion is scientifically justifiable","volume":"138","author":"Watts","year":"2019","journal-title":"Acta Neuropathol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00441-018-2814-1","article-title":"The concept of alpha-synuclein as a prion-like protein: ten years after","volume":"373","author":"Steiner","year":"2018","journal-title":"Cell Tissue Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40265-019-01104-1","article-title":"Targeting alpha-synuclein in Parkinson's disease: progress towards the development of disease-modifying therapeutics","volume":"79","author":"Savitt","year":"2019","journal-title":"Drugs."},{"key":"B35","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/cells10020375","article-title":"Alpha-synuclein: mechanisms of release and pathology progression in synucleinopathies","volume":"10","author":"Bras","year":"2021","journal-title":"Cells"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.1523\/JNEUROSCI.0692-05.2005","article-title":"Intravesicular localization and exocytosis of alpha-synuclein and its aggregates","volume":"25","author":"Lee","year":"2005","journal-title":"J Neurosci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"6838","DOI":"10.1523\/JNEUROSCI.5699-09.2010","article-title":"Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival1","volume":"30","author":"Emmanouilidou","year":"2010","journal-title":"J Neurosci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1089\/ars.2011.4429","article-title":"Lipid peroxidation product 4-hydroxy-2-nonenal promotes seeding-capable oligomer formation and cell-to-cell transfer of alpha-synuclein","volume":"18","author":"Bae","year":"2013","journal-title":"Antioxid Redox Signal."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/j.1471-4159.2010.06695.x","article-title":"Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions","volume":"113","author":"Jang","year":"2010","journal-title":"J Neurochem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3858\/emm.2011.43.4.026","article-title":"Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers","volume":"43","author":"Lee","year":"2011","journal-title":"Exp Mol Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40478-015-0198-y","article-title":"Neuron-to-neuron alpha-synuclein propagation in vivo is independent of neuronal injury","volume":"3","author":"Ulusoy","year":"2015","journal-title":"Acta Neuropathol Commun."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.jprot.2010.06.006","article-title":"Exosomes: extracellular organelles important in intercellular communication","volume":"73","author":"Mathivanan","year":"2010","journal-title":"J Proteomics."},{"key":"B43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00018-017-2595-9","article-title":"Current knowledge on exosome biogenesis and release","volume":"75","author":"Hessvik","year":"2018","journal-title":"Cell Mol Life Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/cells8060565","article-title":"Autophagy in synucleinopathy: the overwhelmed and defective machinery","volume":"8","author":"Arotcarena","year":"2019","journal-title":"Cells"},{"key":"B45","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.nbd.2011.01.029","article-title":"Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission3","volume":"42","author":"Alvarez-Erviti","year":"2011","journal-title":"Neurobiol Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1326-7-42","article-title":"Exosomal cell-to-cell transmission of alpha synuclein oligomers","volume":"7","author":"Danzer","year":"2012","journal-title":"Mol Neurodegener."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1038\/emm.2013.45","article-title":"Autophagic failure promotes the exocytosis and intercellular transfer of alpha-synuclein","volume":"45","author":"Lee","year":"2013","journal-title":"Exp Mol Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.mehy.2007.12.003","article-title":"Exosomes: the Trojan horses of neurodegeneration","volume":"70","author":"Ghidoni","year":"2008","journal-title":"Med Hypotheses."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1074\/jbc.M114.585703","article-title":"Acceleration of alpha-synuclein aggregation by exosomes","volume":"290","author":"Grey","year":"2015","journal-title":"J Biol Chem."},{"key":"B50","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00401-014-1314-y","article-title":"Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson's disease","volume":"128","author":"Shi","year":"2014","journal-title":"Acta Neuropathol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/ene.14208","article-title":"A longitudinal study on alpha-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression","volume":"27","author":"Niu","year":"2020","journal-title":"Eur J Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1002\/mds.28639","article-title":"alpha-synuclein in plasma-derived extracellular vesicles is a potential biomarker of Parkinson's disease","volume":"36","author":"Stuendl","year":"2021","journal-title":"Mov Disord."},{"key":"B53","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.neuroscience.2021.06.033","article-title":"Investigation of alpha-synuclein species in plasma exosomes and the oligomeric and phosphorylated alpha-synuclein as potential peripheral biomarker of Parkinson's disease","volume":"469","author":"Zheng","year":"2021","journal-title":"Neuroscience."},{"key":"B54","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41419-019-1404-9","article-title":"Microglia as modulators of exosomal alpha-synuclein transmission","volume":"10","author":"Xia","year":"2019","journal-title":"Cell Death Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1093\/brain\/awaa090","article-title":"Microglial exosomes facilitate alpha-synuclein transmission in Parkinson's disease","volume":"143","author":"Guo","year":"2020","journal-title":"Brain."},{"key":"B56","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/glia.22437","article-title":"Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia","volume":"61","author":"Fellner","year":"2013","journal-title":"Glia."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/ncomms2534","article-title":"Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia","volume":"4","author":"Kim","year":"2013","journal-title":"Nat Commun."},{"key":"B58","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.bbrc.2019.07.084","article-title":"Extracellular microvesicles-derived from microglia treated with unaggregated alpha-synuclein attenuate mitochondrial fission and toxicity-induced by Parkinsonian toxin MPP","volume":"517","author":"Li","year":"2019","journal-title":"Biochem Biophys Res Commun."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1093\/brain\/awab122","article-title":"Reactive microglia enhance the transmission of exosomal alpha-synuclein via toll-like receptor 2","volume":"144","author":"Xia","year":"2021","journal-title":"Brain"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/s41467-020-15119-w","article-title":"Microglia clear neuron-released alpha-synuclein via selective autophagy and prevent neurodegeneration","volume":"11","author":"Choi","year":"2020","journal-title":"Nat Commun."},{"key":"B61","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.neulet.2013.06.009","article-title":"Exosomes of BV-2 cells induced by alpha-synuclein: important mediator of neurodegeneration in PD","volume":"548","author":"Chang","year":"2013","journal-title":"Neurosci Lett."},{"key":"B62","doi-asserted-by":"publisher","first-page":"ra45","DOI":"10.1126\/scisignal.2005965","article-title":"Activation of MyD88-dependent TLR1\/2 signaling by misfolded alpha-synuclein, a protein linked to neurodegenerative disorders","volume":"8","author":"Daniele","year":"2015","journal-title":"Sci Signal."},{"key":"B63","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12974-015-0455-9","article-title":"Hypoestoxide reduces neuroinflammation and alpha-synuclein accumulation in a mouse model of Parkinson's disease","volume":"12","author":"Kim","year":"2015","journal-title":"J Neuroinflammation."},{"key":"B64","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12974-015-0320-x","article-title":"Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease","volume":"12","author":"Valera","year":"2015","journal-title":"J Neuroinflammation."},{"key":"B65","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00401-019-02007-x","article-title":"Binding of alpha-synuclein oligomers to Cx32 facilitates protein uptake and transfer in neurons and oligodendrocytes","volume":"138","author":"Reyes","year":"2019","journal-title":"Acta Neuropathol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/glia.23631","article-title":"Connexin 43 hemichannels and pannexin-1 channels contribute to the alpha-synuclein-induced dysfunction and death of astrocytes","volume":"67","author":"Diaz","year":"2019","journal-title":"Glia."},{"key":"B67","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3390\/cells9040846","article-title":"Role of Connexins 30, 36, and 43 in brain tumors, neurodegenerative diseases, and neuroprotection","volume":"9","author":"Sanchez","year":"2020","journal-title":"Cells"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.15252\/embj.201593411","article-title":"Tunneling nanotubes spread fibrillar alpha-synuclein by intercellular trafficking of lysosomes","volume":"35","author":"Abounit","year":"2016","journal-title":"EMBO J."},{"key":"B69","doi-asserted-by":"publisher","first-page":"42984","DOI":"10.1038\/srep42984","article-title":"alpha-synuclein transfer through tunneling nanotubes occurs in SH-SY5Y cells and primary brain pericytes from Parkinson's disease patients","volume":"7","author":"Dieriks","year":"2017","journal-title":"Sci Rep."},{"key":"B70","doi-asserted-by":"publisher","first-page":"11835","DOI":"10.1523\/JNEUROSCI.0983-17.2017","article-title":"Human astrocytes transfer aggregated alpha-synuclein via tunneling nanotubes","volume":"37","author":"Rostami","year":"2017","journal-title":"J Neurosci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00441-012-1518-1","article-title":"The molecular basis of induction and formation of tunneling nanotubes","volume":"352","author":"Kimura","year":"2013","journal-title":"Cell Tissue Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"104609","DOI":"10.1016\/j.nbd.2019.104609","article-title":"Human NPCs can degrade alpha-syn fibrils and transfer them preferentially in a cell contact-dependent manner possibly through TNT-like structures","volume":"132","author":"Grudina","year":"2019","journal-title":"Neurobiol Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1016\/j.cell.2021.09.007","article-title":"Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes","volume":"184","author":"Scheiblich","year":"2021","journal-title":"Cell"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e101230","DOI":"10.15252\/embj.2018101230","article-title":"Hasegawa, van Woerden GM, Trollet C, Zurzolo C. The Wnt\/Ca(2+) pathway is involved in interneuronal communication mediated by tunneling nanotubes","volume":"38","author":"Vargas","year":"2019","journal-title":"EMBO J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.biocel.2008.01.017","article-title":"Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein","volume":"40","author":"Lee","year":"2008","journal-title":"Int J Biochem Cell Biol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1074\/jbc.M115.705095","article-title":"Effects of serine 129 phosphorylation on alpha-synuclein aggregation, membrane association, and internalization","volume":"291","author":"Samuel","year":"2016","journal-title":"J Biol Chem."},{"key":"B77","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/jnc.13743","article-title":"Proteolysis of alpha-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology","volume":"140","author":"Sacino","year":"2017","journal-title":"J Neurochem."},{"key":"B78","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ana.23747","article-title":"Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal transport","volume":"72","author":"Freundt","year":"2012","journal-title":"Ann Neurol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00401-016-1538-0","article-title":"Axonal transport and secretion of fibrillar forms of alpha-synuclein, Abeta42 peptide and HTTExon 1","volume":"131","author":"Brahic","year":"2016","journal-title":"Acta Neuropathol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e39465","DOI":"10.1371\/journal.pone.0039465","article-title":"Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo","volume":"7","author":"Angot","year":"2012","journal-title":"PLoS ONE."},{"key":"B81","doi-asserted-by":"publisher","first-page":"E3138","DOI":"10.1073\/pnas.1301440110","article-title":"Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds","volume":"110","author":"Holmes","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B82","doi-asserted-by":"publisher","first-page":"16543","DOI":"10.1038\/s41598-019-53038-z","article-title":"Contribution of syndecans to cellular uptake and fibrillation of alpha-synuclein and tau","volume":"9","author":"Hudak","year":"2019","journal-title":"Sci Rep."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e3000318","DOI":"10.1371\/journal.pbio.3000318","article-title":"Identification of N-linked glycans as specific mediators of neuronal uptake of acetylated alpha-Synuclein","volume":"17","author":"Birol","year":"2019","journal-title":"PLoS Biol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"aah3374","DOI":"10.1126\/science.aah3374","article-title":"Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3","volume":"353","author":"Mao","year":"2016","journal-title":"Science"},{"key":"B85","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/biology9040086","article-title":"Lymphocyte-activation gene 3 (LAG3) protein as a possible therapeutic target for Parkinson's disease: molecular mechanisms connecting neuroinflammation to alpha-synuclein spreading pathology","volume":"9","author":"Angelopoulou","year":"2020","journal-title":"Biology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.celrep.2017.12.009","article-title":"Prion-like propagation of alpha-synuclein is regulated by the FcgammaRIIB-SHP-1\/2 signaling pathway in neurons","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Rep."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e14745","DOI":"10.15252\/emmm.202114745","article-title":"LAG3 is not expressed in human and murine neurons and does not modulate alpha-synucleinopathies","volume":"13","author":"Emmenegger","year":"2021","journal-title":"EMBO Mol Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00401-006-0119-z","article-title":"Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration","volume":"112","author":"Croisier","year":"2006","journal-title":"Acta Neuropathol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"9262","DOI":"10.1074\/jbc.M109.081125","article-title":"Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies","volume":"285","author":"Lee","year":"2010","journal-title":"J Biol Chem."},{"key":"B90","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00401-017-1746-2","article-title":"alpha-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading","volume":"134","author":"Loria","year":"2017","journal-title":"Acta Neuropathol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1750-1326-7-38","article-title":"Suppression of dynamin GTPase decreases alpha-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy","volume":"7","author":"Konno","year":"2012","journal-title":"Mol Neurodegener."},{"key":"B92","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/j.1471-4159.2009.06150.x","article-title":"On the mechanism of internalization of alpha-synuclein into microglia: roles of ganglioside GM1 and lipid raft","volume":"110","author":"Park","year":"2009","journal-title":"J Neurochem."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1073\/pnas.1808845116","article-title":"alpha-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease","volume":"116","author":"Levine","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B94","doi-asserted-by":"publisher","first-page":"10062","DOI":"10.1021\/acs.jmedchem.9b01090","article-title":"Discovery of MK-8719, a potent O-GlcNAcase inhibitor as a potential treatment for tauopathies","volume":"62","author":"Selnick","year":"2019","journal-title":"J Med Chem."},{"key":"B95","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/febs.15349","article-title":"Pharmacological inhibition and knockdown of O-GlcNAcase reduces cellular internalization of alpha-synuclein preformed fibrils","volume":"288","author":"Tavassoly","year":"2021","journal-title":"FEBS J."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-200706\/v1","article-title":"Maturing autophagosomes are transported towards the cell periphery","author":"Hilverling","year":"2021","journal-title":"Cell Mol Neurobiol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"42","DOI":"10.15252\/embj.201695081","article-title":"Dedicated SNAREs and specialized TRIM cargo receptors mediate secretory autophagy","volume":"36","author":"Kimura","year":"2017","journal-title":"EMBO J."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1523\/JNEUROSCI.3809-03.2004","article-title":"Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway","volume":"24","author":"Lee","year":"2004","journal-title":"J Neurosci."},{"key":"B99","doi-asserted-by":"publisher","first-page":"8053","DOI":"10.1523\/JNEUROSCI.21-20-08053.2001","article-title":"Induction of alpha-synuclein aggregation by intracellular nitrative insult","volume":"21","author":"Paxinou","year":"2001","journal-title":"J Neurosci."},{"key":"B100","doi-asserted-by":"publisher","first-page":"25009","DOI":"10.1074\/jbc.M300227200","article-title":"Alpha-Synuclein is degraded by both autophagy and the proteasome","volume":"278","author":"Webb","year":"2003","journal-title":"J Biol Chem."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1001\/archneurol.2010.198","article-title":"Chaperone-mediated autophagy markers in Parkinson disease brains","volume":"67","author":"Alvarez-Erviti","year":"2010","journal-title":"Arch Neurol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1126\/science.1101738","article-title":"Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy","volume":"305","author":"Cuervo","year":"2004","journal-title":"Science."},{"key":"B103","doi-asserted-by":"publisher","first-page":"15194","DOI":"10.1074\/jbc.M113.457408","article-title":"Lewy body-like alpha-synuclein aggregates resist degradation and impair macroautophagy","volume":"288","author":"Tanik","year":"2013","journal-title":"J Biol Chem."},{"key":"B104","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/15548627.2019.1603545","article-title":"Age-dependent accumulation of oligomeric SNCA\/alpha-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA)","volume":"16","author":"Ho","year":"2020","journal-title":"Autophagy."},{"key":"B105","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11910-018-0860-4","article-title":"GBA-associated Parkinson's disease and other synucleinopathies","volume":"18","author":"Gan-Or","year":"2018","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B106","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell."},{"key":"B107","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.nbd.2015.09.009","article-title":"Glucocerebrosidase gene therapy prevents alpha-synucleinopathy of midbrain dopamine neurons","volume":"82","author":"Rocha","year":"2015","journal-title":"Neurobiol Dis."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1093\/hmg\/ddw124","article-title":"Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease","volume":"25","author":"Rockenstein","year":"2016","journal-title":"Hum Mol Genet."},{"key":"B109","doi-asserted-by":"publisher","first-page":"20945","DOI":"10.1038\/s41598-021-00404-5","article-title":"Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model","volume":"11","author":"Viel","year":"2021","journal-title":"Sci Rep."},{"key":"B110","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.nbd.2015.06.008","article-title":"Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells","volume":"82","author":"Ambrosi","year":"2015","journal-title":"Neurobiol Dis."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain."},{"key":"B112","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.neuron.2021.10.032","article-title":"Rescue of alpha-synuclein aggregation in Parkinson's patient neurons by synergistic enhancement of ER proteostasis and protein trafficking","volume":"110","author":"Stojkovska","year":"2022","journal-title":"Neuron"},{"key":"B114","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.neuron.2019.09.001","article-title":"Stress-induced cellular clearance is mediated by the SNARE protein ykt6 and disrupted by alpha-synuclein","volume":"104","author":"Cuddy","year":"2019","journal-title":"Neuron"},{"key":"B115","doi-asserted-by":"publisher","first-page":"28743","DOI":"10.3402\/pba.v5.28743","article-title":"Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy","volume":"5","author":"Bai","year":"2015","journal-title":"Pathobiol Aging Age Relat Dis."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1523\/JNEUROSCI.3944-09.2010","article-title":"Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease","volume":"30","author":"Malagelada","year":"2010","journal-title":"J Neurosci."},{"key":"B117","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.neuroscience.2009.08.014","article-title":"Rapamycin protects against rotenone-induced apoptosis through autophagy induction","volume":"164","author":"Pan","year":"2009","journal-title":"Neuroscience."},{"key":"B118","doi-asserted-by":"publisher","first-page":"E1817","DOI":"10.1073\/pnas.1305623110","article-title":"TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity","volume":"110","author":"Decressac","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B119","doi-asserted-by":"publisher","first-page":"e129719","DOI":"10.1172\/jci.insight.129719","article-title":"Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies","volume":"4","author":"Arotcarena","year":"2019","journal-title":"JCI Insight"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2013.11.002","article-title":"The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro","volume":"63","author":"Dulovic","year":"2014","journal-title":"Neurobiol Dis."},{"key":"B121","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1007\/s12035-015-9173-7","article-title":"Treatment with trehalose prevents behavioral and neurochemical deficits produced in an AAV alpha-synuclein rat model of Parkinson's disease","volume":"53","author":"He","year":"2016","journal-title":"Mol Neurobiol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum Mol Genet."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pbb.2018.12.005","article-title":"Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson's disease","volume":"177","author":"Pupyshev","year":"2019","journal-title":"Pharmacol Biochem Behav."},{"key":"B124","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/cells10010095","article-title":"Spermidine and rapamycin reveal distinct autophagy flux response and cargo receptor clearance profile","volume":"10","author":"de Wet","year":"2021","journal-title":"Cells"},{"key":"B125","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pneurobio.2017.03.006","article-title":"Autophagic flux control in neurodegeneration: Progress and precision targeting-Where do we stand?","volume":"153","author":"Lumkwana","year":"2017","journal-title":"Prog Neurobiol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"e108863","DOI":"10.15252\/embj.2021108863","article-title":"Autophagy in major human diseases","volume":"40","author":"Klionsky","year":"2021","journal-title":"EMBO J."},{"key":"B127","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/cdd.2014.143","article-title":"Autosis and autophagic cell death: the dark side of autophagy","volume":"22","author":"Liu","year":"2015","journal-title":"Cell Death Differ."},{"key":"B128","doi-asserted-by":"publisher","first-page":"e62143","DOI":"10.1371\/journal.pone.0062143","article-title":"Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis","volume":"8","author":"Freeman","year":"2013","journal-title":"PLoS ONE."},{"key":"B129","doi-asserted-by":"publisher","first-page":"7690","DOI":"10.1038\/s41598-017-08149-w","article-title":"Impaired endo-lysosomal membrane integrity accelerates the seeding progression of alpha-synuclein aggregates","volume":"7","author":"Jiang","year":"2017","journal-title":"Sci Rep."},{"key":"B130","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00401-017-1722-x","article-title":"Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins","volume":"134","author":"Flavin","year":"2017","journal-title":"Acta Neuropathol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","article-title":"Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes","volume":"22","author":"Shahmoradian","year":"2019","journal-title":"Nat Neurosci."},{"key":"B132","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1038\/ncomms6857","article-title":"Small molecule-mediated stabilization of vesicle-associated helical alpha-synuclein inhibits pathogenic misfolding and aggregation","volume":"5","author":"Fonseca-Ornelas","year":"2014","journal-title":"Nat Commun."},{"key":"B133","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3233\/JPD-202221","article-title":"Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions","volume":"11","author":"Castonguay","year":"2021","journal-title":"J Parkinsons Dis."},{"key":"B134","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron."},{"key":"B135","doi-asserted-by":"publisher","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS ONE."},{"key":"B136","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/NEN.0b013e31829768d2","article-title":"alpha-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model","volume":"72","author":"Sanchez-Guajardo","year":"2013","journal-title":"J Neuropathol Exp Neurol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1080\/21645515.2015.1012033","article-title":"Evaluation of an alpha synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson's disease","volume":"11","author":"Ugen","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"B138","doi-asserted-by":"publisher","first-page":"e0181844","DOI":"10.1371\/journal.pone.0181844","article-title":"Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles","volume":"12","author":"Doucet","year":"2017","journal-title":"PloS ONE."},{"key":"B139","doi-asserted-by":"publisher","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J Neurosci."},{"key":"B140","doi-asserted-by":"publisher","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J Neurosci."},{"key":"B141","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.celrep.2014.05.033","article-title":"Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration","volume":"7","author":"Tran","year":"2014","journal-title":"Cell Rep."},{"key":"B142","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-016-0410-8","article-title":"Anti-alpha-synuclein immunotherapy reduces alpha-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy","volume":"5","author":"Spencer","year":"2017","journal-title":"Acta Neuropathol Commun."},{"key":"B143","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.nbd.2017.05.002","article-title":"Differential effects of immunotherapy with antibodies targeting alpha-synuclein oligomers and fibrils in a transgenic model of synucleinopathy","volume":"104","author":"El-Agnaf","year":"2017","journal-title":"Neurobiol Dis."},{"key":"B144","doi-asserted-by":"publisher","first-page":"104582","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity alpha-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular alpha-synuclein and attenuate alpha-synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiol Dis."},{"key":"B145","doi-asserted-by":"publisher","first-page":"104712","DOI":"10.1016\/j.nbd.2019.104712","article-title":"Characterization of novel conformation-selective alpha-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease","volume":"136","author":"Henderson","year":"2020","journal-title":"Neurobiol Dis."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the alpha-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1002\/mds.28218","article-title":"Rascol, and AInvestigators FFS A Phase 1 randomized trial of specific active alpha-synuclein immunotherapies PD01A and PD03A in multiple system atrophy","volume":"35","author":"Meissner","year":"2020","journal-title":"Mov Disord."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3233\/JPD-212594","article-title":"Safety and tolerability of active immunotherapy targeting alpha-synuclein with PD03A in patients with early Parkinson's disease: a randomized, placebo-controlled, phase 1","volume":"11","author":"Poewe","year":"2021","journal-title":"Study J Parkinsons Dis"},{"key":"B151","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13195-020-00727-x","article-title":"Novel antibodies detect additional alpha-synuclein pathology in synucleinopathies: potential development for immunotherapy","volume":"12","author":"Nimmo","year":"2020","journal-title":"Alzheimers Res Ther."},{"key":"B152","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol Dis."},{"key":"B153","doi-asserted-by":"publisher","first-page":"733857","DOI":"10.3389\/fnins.2021.733857","article-title":"Amyloid-beta and alpha-synuclein immunotherapy: from experimental studies to clinical trials","volume":"15","author":"Nimmo","year":"2021","journal-title":"Front Neurosci."},{"key":"B154","doi-asserted-by":"publisher","first-page":"104707","DOI":"10.1016\/j.nbd.2019.104707","article-title":"Advances and considerations in AD tau-targeted immunotherapy","volume":"134","author":"Bittar","year":"2020","journal-title":"Neurobiol Dis."},{"key":"B155","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/cells8020105","article-title":"Novel immunotherapeutic approaches to target alpha-synuclein and related neuroinflammation in Parkinson's disease","volume":"8","author":"Zella","year":"2019","journal-title":"Cells"},{"key":"B156","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1038\/s41467-018-05971-2","article-title":"Cryo-EM of full-length alpha-synuclein reveals fibril polymorphs with a common structural kernel","volume":"9","author":"Li","year":"2018","journal-title":"Nat Commun."},{"key":"B157","doi-asserted-by":"publisher","first-page":"e48907","DOI":"10.7554\/eLife.48907","article-title":"Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy","volume":"8","author":"Guerrero-Ferreira","year":"2019","journal-title":"Elife"},{"key":"B158","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41586-020-2317-6","article-title":"Structures of alpha-synuclein filaments from multiple system atrophy","volume":"585","author":"Schweighauser","year":"2020","journal-title":"Nature."},{"key":"B159","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40035-022-00283-4","article-title":"Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy","volume":"11","author":"Martinez-Valbuena","year":"2022","journal-title":"Transl Neurodegener."},{"key":"B160","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1750-1326-3-19","article-title":"In vivo silencing of alpha-synuclein using naked siRNA","volume":"3","author":"Lewis","year":"2008","journal-title":"Mol Neurodegener."},{"key":"B161","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.expneurol.2005.12.024","article-title":"Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi","volume":"198","author":"Sapru","year":"2006","journal-title":"ExpNeurol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.brainres.2011.04.036","article-title":"An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons","volume":"1395","author":"Khodr","year":"2011","journal-title":"Brain Res."},{"key":"B163","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.brainres.2014.01.010","article-title":"Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects","volume":"1550","author":"Khodr","year":"2014","journal-title":"Brain Res."},{"key":"B164","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.nbd.2019.01.004","article-title":"Long-term RNAi knockdown of alpha-synuclein in the adult rat substantia nigra without neurodegeneration","volume":"125","author":"Zharikov","year":"2019","journal-title":"Neurobiol Dis."},{"key":"B165","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fnins.2016.00012","article-title":"Is alpha-synuclein loss-of-function a contributor to parkinsonian pathology? evidence from non-human primates","volume":"10","author":"Collier","year":"2016","journal-title":"Front Neurosci."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/mt.2010.115","article-title":"In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration2","volume":"18","author":"Gorbatyuk","year":"2010","journal-title":"MolTher."},{"key":"B167","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fnmol.2018.00036","article-title":"Silencing alpha synuclein in mature nigral neurons results in rapid neuroinflammation and subsequent toxicity","volume":"11","author":"Benskey","year":"2018","journal-title":"Front Mol Neurosci."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1002\/mds.101","article-title":"Noninvasive delivery of an alpha-synuclein gene silencing vector with magnetic resonance-guided focused ultrasound","volume":"33","author":"Xhima","year":"2018","journal-title":"Mov Disord."},{"key":"B169","doi-asserted-by":"publisher","first-page":"e135633","DOI":"10.1172\/jci.insight.135633","article-title":"Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease","volume":"6","author":"Cole","year":"2021","journal-title":"JCI Insight"},{"key":"B170","doi-asserted-by":"publisher","first-page":"fcab247","DOI":"10.1093\/braincomms\/fcab247","article-title":"Viral alpha-synuclein knockdown prevents spreading synucleinopathy","volume":"3","author":"Menon","year":"2021","journal-title":"Brain Commun"},{"key":"B171","doi-asserted-by":"publisher","first-page":"37043","DOI":"10.18632\/oncotarget.6158","article-title":"Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease","volume":"6","author":"Gui","year":"2015","journal-title":"Oncotarget."},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-021-01093-4","article-title":"Role of MicroRNAs, aptamers in neuroinflammation and neurodegenerative disorders","author":"Khan","year":"2021","journal-title":"Cell Mol Neurobiol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"13052","DOI":"10.1073\/pnas.0906277106","article-title":"Repression of alpha-synuclein expression and toxicity by microRNA-7","volume":"106","author":"Junn","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B174","doi-asserted-by":"publisher","first-page":"12726","DOI":"10.1074\/jbc.M109.086827","article-title":"Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153","volume":"285","author":"Doxakis","year":"2010","journal-title":"J Biol Chem."},{"key":"B175","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.biopha.2015.08.025","article-title":"MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting alpha-synuclein expression in MPTP-induced Parkinson's disease mouse","volume":"74","author":"Wang","year":"2015","journal-title":"Biomed Pharmacother."},{"key":"B176","doi-asserted-by":"publisher","first-page":"938348","DOI":"10.1155\/2014\/938348","article-title":"miR-16-1 promotes the aberrant alpha-synuclein accumulation in parkinson disease via targeting heat shock protein 70","volume":"2014","author":"Zhang","year":"2014","journal-title":"ScientificWorldJournal."},{"key":"B177","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.brainres.2011.02.041","article-title":"A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons","volume":"1386","author":"Han","year":"2011","journal-title":"Brain Res."},{"key":"B178","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.brainresbull.2019.05.024","article-title":"Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors","volume":"150","author":"Puhl","year":"2019","journal-title":"Brain Res Bull."},{"key":"B179","doi-asserted-by":"publisher","first-page":"102944","DOI":"10.1016\/j.ebiom.2020.102944","article-title":"Anti-alpha-synuclein ASO delivered to monoamine neurons prevents alpha-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys","volume":"59","author":"Alarcon-Aris","year":"2020","journal-title":"EBioMedicine."},{"key":"B180","doi-asserted-by":"publisher","first-page":"105218","DOI":"10.1016\/j.nbd.2020.105218","article-title":"Exosome-mediated delivery of antisense oligonucleotides targeting alpha-synuclein ameliorates the pathology in a mouse model of Parkinson's disease","volume":"148","author":"Yang","year":"2021","journal-title":"Neurobiol Dis."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3390\/pharmaceutics12121216","article-title":"Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB","volume":"12","author":"Kimura","year":"2020","journal-title":"Pharmaceutics"},{"key":"B182","doi-asserted-by":"publisher","first-page":"135769","DOI":"10.1016\/j.neulet.2021.135769","article-title":"Lentiviral mediated gene delivery as an effective therapeutic approach for Parkinson disease","volume":"750","author":"Kakoty","year":"2021","journal-title":"Neurosci Lett."},{"key":"B183","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1208\/s12248-021-00608-7","article-title":"Non-viral vectors in gene therapy: recent development, challenges, and prospects","volume":"23","author":"Zu","year":"2021","journal-title":"AAPS J."},{"key":"B184","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cell.2011.06.019","article-title":"Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations","volume":"146","author":"Soldner","year":"2011","journal-title":"Cell."},{"key":"B185","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","article-title":"Downregulation of SNCA expression by targeted editing of DNA methylation: a potential strategy for precision therapy in PD","volume":"26","author":"Kantor","year":"2018","journal-title":"Mol Ther."},{"key":"B186","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41551-021-00759-0","article-title":"Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer's disease alleviates amyloid-related pathologies in mice","volume":"6","author":"Duan","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"B187","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.drudis.2006.10.013","article-title":"Blood-brain barrier delivery","volume":"12","author":"Pardridge","year":"2007","journal-title":"Drug Discov Today."},{"key":"B188","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","article-title":"Blood-brain barrier and delivery of protein and gene therapeutics to brain","volume":"11","author":"Pardridge","year":"2019","journal-title":"Front Aging Neurosci."},{"key":"B189","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat Neurosci."},{"key":"B190","doi-asserted-by":"publisher","first-page":"582979","DOI":"10.3389\/fbioe.2020.582979","article-title":"PHPB\/eB vectors bring new successes to gene therapy for brain diseases","volume":"8","author":"Reynaud-Dulaurier","year":"2020","journal-title":"Front Bioeng Biotechnol."},{"key":"B191","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","article-title":"AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset","volume":"25","author":"Goertsen","year":"2021","journal-title":"Nat Neurosci"},{"key":"B192","doi-asserted-by":"publisher","first-page":"685802","DOI":"10.3389\/fneur.2021.685802","article-title":"Toward development of neuron specific transduction after systemic delivery of viral vectors","volume":"12","author":"Finneran","year":"2021","journal-title":"Front Neurol"},{"key":"B193","doi-asserted-by":"publisher","first-page":"e0225206","DOI":"10.1371\/journal.pone.0225206","article-title":"Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHPB capsids","volume":"14","author":"Huang","year":"2019","journal-title":"PloS ONE."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.bbrc.2006.01.057","article-title":"Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model","volume":"341","author":"Hayashita-Kinoh","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"B195","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/mt.2015.232","article-title":"Development of nonviral vectors targeting the brain as a therapeutic approach for parkinson's disease and other brain disorders","volume":"24","author":"Javed","year":"2016","journal-title":"Mol Ther"},{"key":"B196","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.nbd.2019.03.001","article-title":"Systemic peptide mediated delivery of an siRNA targeting alpha-syn in the CNSameliorates the neurodegenerative process in a transgenic model of Lewy body disease","volume":"127","author":"Spencer","year":"2019","journal-title":"Neurobiol Dis"},{"key":"B197","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.nano.2018.01.020","article-title":"Neuroprotective effect of gold nanoparticles composites in Parkinson's disease model","volume":"14","author":"Hu","year":"2018","journal-title":"Nanomedicine"},{"key":"B198","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.omtn.2017.08.013","article-title":"Polyethylenimine nanoparticle-mediated sirna delivery to reduce alpha-synuclein expression in a model of parkinson's disease","volume":"9","author":"Helmschrodt","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"B199","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1002\/mds.25978","article-title":"Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice","volume":"29","author":"Cooper","year":"2014","journal-title":"Mov Disord"},{"key":"B200","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.ymthe.2019.08.010","article-title":"Systemic exosomal delivery of shrna minicircles prevents parkinsonian pathology","volume":"27","author":"Izco","year":"2019","journal-title":"Mol Ther"},{"key":"B201","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ymthe.2017.11.015","article-title":"Selective alpha-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: Potential therapy for parkinson's disease","volume":"26","author":"Alarcon-Aris","year":"2018","journal-title":"Mol Ther"},{"key":"B202","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu Rev Biochem."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/j.1471-4159.2005.03463.x","article-title":"The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells","volume":"95","author":"Abulrob","year":"2005","journal-title":"J Neurochem."},{"key":"B204","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neuroscience.2011.05.076","article-title":"Transmigration of beta amyloid specific heavy chain antibody fragments across the in vitro blood-brain barrier","volume":"190","author":"Rutgers","year":"2011","journal-title":"Neuroscience"},{"key":"B205","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2016.09.019","article-title":"Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets","volume":"243","author":"Li","year":"2016","journal-title":"J Control Release."},{"key":"B206","doi-asserted-by":"publisher","first-page":"104619","DOI":"10.1016\/j.nbd.2019.104619","article-title":"Optimizing intracellular antibodies (intrabodies\/nanobodies) to treat neurodegenerative disorders","volume":"134","author":"Messer","year":"2020","journal-title":"Neurobiol Dis."},{"key":"B207","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s13311-013-0193-6","article-title":"Intrabodies as neuroprotective therapeutics","volume":"10","author":"Messer","year":"2013","journal-title":"Neurotherapeutics."},{"key":"B208","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.bbapap.2014.08.016","article-title":"Antibodies and protein misfolding: From structural research tools to therapeutic strategies","volume":"1844","author":"De Genst","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B209","doi-asserted-by":"publisher","first-page":"8137","DOI":"10.1038\/s41598-020-65035-8","article-title":"Fibrillar form of alpha-synuclein-specific scFv antibody inhibits alpha-synuclein seeds induced aggregation and toxicity","volume":"10","author":"Gupta","year":"2020","journal-title":"Sci Rep."},{"key":"B210","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/j.jmb.2013.01.040","article-title":"De Genst, Nanobodies raised against monomeric alpha-synuclein distinguish between fibrils at different maturation stages","volume":"425","author":"Guilliams","year":"2013","journal-title":"J Mol Biol."},{"key":"B211","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12915-017-0390-6","article-title":"Nanobodies raised against monomeric a-synuclein inhibit fibril formation and destabilize toxic oligomeric species","volume":"15","author":"Iljina","year":"2017","journal-title":"BMC Biol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41531-018-0062-4","article-title":"Proteasome-targeted nanobodies alleviate pathology and functional decline in an alpha-synuclein-based Parkinson's disease model","volume":"4","author":"Chatterjee","year":"2018","journal-title":"NPJ Parkinsons Dis."},{"key":"B213","doi-asserted-by":"publisher","first-page":"e0165964","DOI":"10.1371\/journal.pone.0165964","article-title":"Bifunctional anti-non-amyloid component alpha-synuclein nanobodies are protective in situ","volume":"11","author":"Butler","year":"2016","journal-title":"PLoS ONE"},{"key":"B214","doi-asserted-by":"publisher","first-page":"686","DOI":"10.4161\/mabs.21696","article-title":"Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies","volume":"4","author":"Joshi","year":"2012","journal-title":"MAbs."},{"key":"B215","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1126\/science.aaf3934","article-title":"beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson's disease","volume":"357","author":"Mittal","year":"2017","journal-title":"Science."},{"key":"B216","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.4049\/jimmunol.1002449","article-title":"beta2-adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway","volume":"186","author":"Qian","year":"2011","journal-title":"J Immunol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1093\/brain\/aww238","article-title":"A de novo compound targeting alpha-synuclein improves deficits in models of Parkinson's disease","volume":"139","author":"Wrasidlo","year":"2016","journal-title":"Brain."},{"key":"B218","doi-asserted-by":"publisher","first-page":"16165","DOI":"10.1038\/s41598-018-34490-9","article-title":"The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease","volume":"8","author":"Price","year":"2018","journal-title":"Sci Rep."},{"key":"B219","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","article-title":"Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease","volume":"125","author":"Wagner","year":"2013","journal-title":"Acta Neuropathol."},{"key":"B220","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00401-019-02023-x","article-title":"Depopulation of dense alpha-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model","volume":"138","author":"Wegrzynowicz","year":"2019","journal-title":"Acta Neuropathol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/mds.27562","article-title":"Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy","volume":"34","author":"Heras-Garvin","year":"2019","journal-title":"Mov Disord."},{"key":"B222","doi-asserted-by":"publisher","first-page":"E1009","DOI":"10.1073\/pnas.1610586114","article-title":"A natural product inhibits the initiation of alpha-synuclein aggregation and suppresses its toxicity","volume":"114","author":"Perni","year":"2017","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B223","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1021\/acschembio.8b00466","article-title":"Multistep Inhibition of alpha-Synuclein Aggregation and Toxicity in Vitro and in Vivo by Trodusquemine","volume":"13","author":"Perni","year":"2018","journal-title":"ACS Chem Biol."},{"key":"B224","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s13311-012-0105-1","article-title":"A novel \u201cmolecular tweezer\u201d inhibitor of alpha-synuclein neurotoxicity in vitro and in vivo","volume":"9","author":"Prabhudesai","year":"2012","journal-title":"Neurotherapeutics"},{"key":"B225","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s13311-017-0544-9","article-title":"A molecular tweezer ameliorates motor deficits in mice overexpressing alpha-synuclein","volume":"14","author":"Richter","year":"2017","journal-title":"Neurotherapeutics"},{"key":"B226","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1038\/s41467-020-18689-x","article-title":"CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson's disease","volume":"11","author":"Bengoa-Vergniory","year":"2020","journal-title":"Nat Commun"},{"key":"B227","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nsmb.1437","article-title":"EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers","volume":"15","author":"Ehrnhoefer","year":"2008","journal-title":"Nat Struct Mol Biol."},{"key":"B228","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.3945\/jn.117.255034","article-title":"Epigallocatechin gallate has a neurorescue effect in a mouse model of Parkinson disease","volume":"147","author":"Xu","year":"2017","journal-title":"J Nutr."},{"key":"B229","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.neuroscience.2014.12.003","article-title":"Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral alpha-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys","volume":"286","author":"Chen","year":"2015","journal-title":"Neuroscience."},{"key":"B230","doi-asserted-by":"publisher","first-page":"14941","DOI":"10.1074\/jbc.M110.211029","article-title":"Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease","volume":"286","author":"Zhou","year":"2011","journal-title":"J Biol Chem."},{"key":"B231","doi-asserted-by":"publisher","first-page":"e38113","DOI":"10.1371\/journal.pone.0038113","article-title":"Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease","volume":"7","author":"Roy","year":"2012","journal-title":"PLoS ONE"},{"key":"B232","doi-asserted-by":"publisher","first-page":"10481","DOI":"10.1073\/pnas.1804198115","article-title":"Small molecule inhibits alpha-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons","volume":"115","author":"Pujols","year":"2018","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B233","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s42004-020-00412-y","article-title":"Screening of small molecules using the inhibition of oligomer formation in \u03b1-synuclein aggregation as a selection parameter","volume":"3","author":"Staats","year":"2020","journal-title":"Communications Chemistry."},{"key":"B234","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/j.1476-5381.2012.01846.x","article-title":"A prolyl oligopeptidase inhibitor, KYP-2047, reduces alpha-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease","volume":"166","author":"Myohanen","year":"2012","journal-title":"Br J Pharmacol"},{"key":"B235","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2014.04.003","article-title":"The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse","volume":"68","author":"Savolainen","year":"2014","journal-title":"Neurobiol Dis"},{"key":"B236","doi-asserted-by":"publisher","first-page":"110788","DOI":"10.1016\/j.biopha.2020.110788","article-title":"Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells","volume":"131","author":"Rostami","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"B237","doi-asserted-by":"publisher","first-page":"547","DOI":"10.5607\/en.2019.28.5.547","article-title":"Targeting microglial and neuronal toll-like receptor 2 in synucleinopathies","volume":"28","author":"Kwon","year":"2019","journal-title":"Exp Neurobiol"},{"key":"B238","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3233\/JPD-212877","article-title":"The compound ATH434 prevents alpha-synuclein toxicity in a murine model of multiple system atrophy","volume":"12","author":"Finkelstein","year":"2022","journal-title":"J Parkinsons Dis"},{"key":"B239","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1073\/pnas.1905057117","article-title":"Translation of the intrinsically disordered protein alpha-synuclein is inhibited by a small molecule targeting its structured mRNA","volume":"117","author":"Zhang","year":"2020","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B240","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/mds.108","article-title":"beta2-adrenoceptor agonists and antagonists and risk of Parkinson's disease","volume":"33","author":"Gronich","year":"2018","journal-title":"Mov Disord."},{"key":"B241","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ana.25341","article-title":"Beta2-adrenoreceptor medications and risk of Parkinson disease","volume":"84","author":"Searles Nielsen","year":"2018","journal-title":"Ann Neurol"},{"key":"B242","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11481-012-9410-z","article-title":"Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?","volume":"8","author":"Cosentino","year":"2013","journal-title":"J Neuroimmune Pharmacol."},{"key":"B243","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1212\/WNL.59.4.609","article-title":"Pilot trial of albuterol in spinal muscular atrophy","volume":"59","author":"Kinali","year":"2002","journal-title":"Neurology."},{"key":"B244","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/0140-6736(92)90313-R","article-title":"\u201cWearing-off\u201d and beta 2-adrenoceptor agonist in Parkinson's disease","volume":"339","author":"Hishida","year":"1992","journal-title":"Lancet."},{"key":"B245","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1212\/WNL.44.8.1511","article-title":"Beta 2-adrenergic agonist as adjunct therapy to levodopa in Parkinson's disease","volume":"44","author":"Alexander","year":"1994","journal-title":"Neurology."},{"key":"B246","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00002826-200307000-00011","article-title":"Albuterol improves response to levodopa and increases skeletal muscle mass in patients with fluctuating Parkinson disease","volume":"26","author":"Uc","year":"2003","journal-title":"Clin Neuropharmacol."},{"key":"B247","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S1474-4422(19)30141-3","article-title":"Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial","volume":"18","author":"Levin","year":"2019","journal-title":"Lancet Neurol."},{"key":"B248","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3389\/fphar.2018.01555","article-title":"Plant extracts and phytochemicals targeting alpha-synuclein aggregation in Parkinson's disease models","volume":"9","author":"Javed","year":"2018","journal-title":"Front Pharmacol."},{"key":"B249","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1021\/ar050073t","article-title":"The aggregation and fibrillation of alpha-synuclein","volume":"39","author":"Fink","year":"2006","journal-title":"Acc Chem Res."},{"key":"B250","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neuropharm.2018.05.035","article-title":"Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease","volume":"147","author":"Johnston","year":"2019","journal-title":"Neuropharmacology."},{"key":"B251","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrd3160","article-title":"Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years","volume":"9","author":"Braun","year":"2010","journal-title":"Nat Rev Drug Discov."},{"key":"B252","volume-title":"Drug Repurposing and Repositioning: Workshop Summary.","author":"Medicine","year":"2014"},{"key":"B253","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3233\/JPD-202128","article-title":"Parkinson's disease drug therapies in the clinical trial pipeline: 2020","volume":"10","author":"McFarthing","year":"2020","journal-title":"J Parkinsons Dis."},{"key":"B254","doi-asserted-by":"publisher","first-page":"17579","DOI":"10.1074\/jbc.M112.434787","article-title":"A blood-brain barrier (BBB) disrupter is also a potent alpha-synuclein (alpha-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD)","volume":"288","author":"Shaltiel-Karyo","year":"2013","journal-title":"J Biol Chem."},{"key":"B255","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00401-017-1785-8","article-title":"Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis","volume":"135","author":"Bakkar","year":"2018","journal-title":"Acta Neuropathol."},{"key":"B256","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/pds.5015","article-title":"Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology","volume":"29","author":"Maclagan","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B257","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/pds.5176","article-title":"Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson's disease","volume":"30","author":"Visanji","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B258","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-021-00497-6","article-title":"Small molecule inhibitors of alpha-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans","volume":"16","author":"Chen","year":"2021","journal-title":"Mol Neurodegener."},{"key":"B259","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41582-020-00418-z","article-title":"Applications of focused ultrasound in the brain: from thermoablation to drug delivery","volume":"17","author":"Meng","year":"2021","journal-title":"Nat Rev Neurol."},{"key":"B260","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1001\/archneurpsyc.1956.02330290001001","article-title":"Ultrasonically produced changes in the blood-brain barrier","volume":"76","author":"Bakay","year":"1956","journal-title":"AMA Arch Neurol Psychiatry."},{"key":"B261","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1148\/radiol.2202001804","article-title":"Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits","volume":"220","author":"Hynynen","year":"2001","journal-title":"Radiology."},{"key":"B262","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev-bioeng-062117-121238","article-title":"Therapeutic Agent Delivery Across the Blood-Brain Barrier Using Focused Ultrasound","volume":"23","author":"McMahon","year":"2021","journal-title":"Annu Rev Biomed Eng."},{"key":"B263","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1089\/hum.2012.013","article-title":"Targeted delivery of scAAV9 to the brain using MRI-guided focused ultrasound","volume":"11","author":"Thevenot","year":"2012","journal-title":"Hum Gene Ther"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab460","article-title":"Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies","author":"Xhima","year":"2021","journal-title":"Brain"},{"key":"B265","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1038\/s41467-019-12426-9","article-title":"First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound","volume":"10","author":"Abrahao","year":"2019","journal-title":"Nat Commun."},{"key":"B266","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1038\/s41467-018-04529-6","article-title":"Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound","volume":"9","author":"Lipsman","year":"2018","journal-title":"Nat Commun."},{"key":"B267","doi-asserted-by":"publisher","first-page":"9180","DOI":"10.1073\/pnas.2002571117","article-title":"Noninvasive hippocampal blood-brain barrier opening in Alzheimer's disease with focused ultrasound","volume":"117","author":"Rezai","year":"2020","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B268","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41467-021-21022-9","article-title":"Blood-brain barrier opening with focused ultrasound in Parkinson's disease dementia","volume":"12","author":"Gasca-Salas","year":"2021","journal-title":"Nat Commun."},{"key":"B269","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40035-021-00269-8","article-title":"Extensive frontal focused ultrasound mediated blood-brain barrier opening for the treatment of Alzheimer's disease: a proof-of-concept study","volume":"10","author":"Park","year":"2021","journal-title":"Transl Neurodegener."},{"key":"B270","doi-asserted-by":"publisher","first-page":"19579","DOI":"10.1038\/srep19579","article-title":"Targeted, and Non-Viral Ultrasound-Mediated GDNF-Plasmid Delivery for Treatment of Parkinson's Disease","volume":"6","author":"Fan","year":"2016","journal-title":"Sci Rep."},{"key":"B271","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jconrel.2016.05.052","article-title":"Non-invasive, neuron-specific gene therapy by focused ultrasound-induced blood-brain barrier opening in Parkinson's disease mouse model","volume":"235","author":"Lin","year":"2016","journal-title":"J Control Release."},{"key":"B272","doi-asserted-by":"publisher","first-page":"28599","DOI":"10.1038\/srep28599","article-title":"Focused ultrasound-enhanced intranasal brain delivery of brain-derived neurotrophic factor","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep."},{"key":"B273","doi-asserted-by":"publisher","first-page":"19402","DOI":"10.1038\/s41598-019-55294-5","article-title":"Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson's disease mouse model","volume":"9","author":"Ji","year":"2019","journal-title":"Sci Rep."},{"key":"B274","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.expneurol.2013.05.008","article-title":"Amyloid-beta plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound","volume":"248","author":"Jordao","year":"2013","journal-title":"Exp Neurol."},{"key":"B275","doi-asserted-by":"publisher","first-page":"4784268","DOI":"10.1155\/2018\/4784268","article-title":"Linking neuroinflammation and neurodegeneration in Parkinson's disease","volume":"2018","author":"Gelders","year":"2018","journal-title":"J Immunol Res."},{"key":"B276","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/373335a0","article-title":"Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo","volume":"373","author":"Tomac","year":"1995","journal-title":"Nature"},{"key":"B277","doi-asserted-by":"publisher","first-page":"eaax6646","DOI":"10.1126\/sciadv.aax6646","article-title":"Focused ultrasound delivery of a selective TrkA agonist rescues cholinergic function in a mouse model of Alzheimer's disease","volume":"6","author":"Xhima","year":"2020","journal-title":"Sci Adv"},{"key":"B278","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","article-title":"The blood-brain barrier in health and chronic neurodegenerative disorders","volume":"57","author":"Zlokovic","year":"2008","journal-title":"Neuron."},{"key":"B279","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","article-title":"Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC","volume":"6","author":"Groveman","year":"2018","journal-title":"Acta Neuropathol Commun."},{"key":"B280","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.nbd.2019.05.002","article-title":"Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification","volume":"129","author":"Fenyi","year":"2019","journal-title":"Neurobiol Dis."},{"key":"B281","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-1-4939-8820-4_2","article-title":"Ultrasensitive RT-QuIC seed amplification assays for disease-associated tau, alpha-synuclein, prion aggregates","volume":"1873","author":"Saijo","year":"2019","journal-title":"Methods Mol Biol."},{"key":"B282","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","article-title":"Discriminating alpha-synuclein strains in Parkinson's disease and multiple system atrophy","volume":"578","author":"Shahnawaz","year":"2020","journal-title":"Nature."},{"key":"B283","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaneurol.2020.3311","article-title":"Skin alpha-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease","volume":"78","author":"Wang","year":"2020","journal-title":"JAMA Neurol"},{"key":"B284","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/mds.28242","article-title":"Blinded RT-QuIC analysis of alpha-synuclein biomarker in skin tissue from Parkinson's disease patients","volume":"35","author":"Manne","year":"2020","journal-title":"Mov Disord."},{"key":"B285","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/mds.27802","article-title":"Update of the MDS research criteria for prodromal Parkinson's disease","volume":"34","author":"Heinzel","year":"2019","journal-title":"Mov Disord."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.852003\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T02:36:37Z","timestamp":1652063797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.852003\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":285,"alternative-id":["10.3389\/fneur.2022.852003"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.852003","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742165492.793593425","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.742165492.793593595","asserted-by":"object"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"article-number":"852003"}}